Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!
Aug 08, 2017
Failure of Phase II cannabidiol trial leads to loss for Zynerba Zynerba Pharmaceuticals’ phase II trial for transdermal cannabinoid candidate missed all its endpoints, as it failed to hit a single goal or show a dose response raises big doubts about the drug's prospects. This news eroded around 55% off Zynerba’s sto...
Read More...
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Transforming Multiple Myeloma Treatment: The Promise of Novel Drug Classes
Jul 24, 2024
-Agonist.png "Toll-like Receptors Agonist")
Newsletter/Whitepaper